Search

Arvinas Inc

Cerrado

SectorSanidad

8.27 -0.36

Resumen

Variación precio

24h

Actual

Mínimo

8.18

Máximo

8.28

Métricas clave

By Trading Economics

Ingresos

227M

169M

Ventas

234M

250M

P/B

Media del Sector

32.308

56.432

BPA

2.58

Margen de beneficios

67.841

Empleados

246

EBITDA

216M

159M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+80.51% upside

Dividendos

By Acuity

Próximas Ganancias

4 nov 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

29M

549M

Apertura anterior

8.63

Cierre anterior

8.27

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

115 / 339 Clasificación en Healthcare

Arvinas Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

17 sept 2026, 19:36 UTC

Arvinas Inc is higher today, advancing since Wednesday's close, despite earlier pulling back from a session high but remaining above its opening level.

16 sept 2026, 19:03 UTC

Arvinas Inc shares fell sharply, continuing a downward trend and remaining below the 20-day moving average, with no recovery from an early dip.

15 sept 2026, 20:02 UTC

Arvinas Inc shares are trading lower, marking six consecutive daily declines. The stock remains below its 20-day moving average amid negative market sentiment.

11 sept 2026, 20:08 UTC

Arvinas Inc. shares are lower today, remaining below their 20-day moving average amid broader market inflation concerns following recent Consumer Price Index data.

10 sept 2026, 20:07 UTC

Arvinas Inc shares are lower today, marking four consecutive sessions of declines amid broader market trends and rising Treasury yields.

2 sept 2026, 19:46 UTC

Arvinas Inc shares are higher during Wednesday's session, showing unusual strength despite a slight pullback from earlier highs. No specific news was identified.

28 ago 2026, 20:08 UTC

Arvinas Inc. shares are lower as U.S. Treasury yields rise amid inflation concerns. Trading remains routine, with shares finishing below earlier highs.

27 ago 2026, 19:36 UTC

Arvinas Inc. shares are higher during Thursday's session, trading within a narrow range and above the 20-day moving average.

26 ago 2026, 20:08 UTC

Arvinas Inc shares are lower today as the pharmaceuticals sub-sector declines amid broader market weakness since Tuesday's close. No specific news was identified.

25 ago 2026, 23:01 UTC

Arvinas Inc shares are higher in after-market trading amid a broader positive sentiment following a decrease in crude oil prices and U.S. sanctions on Iran.

24 ago 2026, 19:56 UTC

Arvinas Inc. shares are lower today amid broader market pressures, including a significant drop in crude oil prices linked to U.S.-Iran relations.

21 ago 2026, 19:56 UTC

Arvinas Inc is trading higher, reflecting broader market gains despite no specific company news. The stock remains above its 20-day moving average.

20 ago 2026, 20:01 UTC

Arvinas Inc shares are lower today, reflecting broader market pressures amid concerns over consumer spending following Walmart Inc's disappointing earnings report.

19 ago 2026, 19:26 UTC

News

Arvinas Inc shares are higher, buoyed by positive analyst ratings. BTIG maintains a "buy" with an $18 target, while Barclays raises its target to $20.

17 ago 2026, 19:16 UTC

Arvinas Inc shares are higher during Monday's session, reflecting positive market performance. The stock has gained since Friday's close, despite a decline in retail sales.

14 ago 2026, 19:46 UTC

Arvinas Inc shares are lower amid significant downward pressure in the Pharmaceuticals sub-sector. The stock remains above its 20-day moving average.

13 ago 2026, 19:46 UTC

Arvinas Inc. shares are higher today, maintaining a position above their 20-day moving average and near the upper end of their one-month range.

11 ago 2026, 19:26 UTC

Arvinas Inc. shares are trading lower as the Pharmaceuticals sub-sector declines, despite a peak shortly after the market opened. No specific news was identified.

10 ago 2026, 19:56 UTC

News

Analysts updated ratings on Arvinas Inc, with Citigroup lowering its target to $21 and Evercore ISI reducing its target to $14. Shares are trading higher.

7 ago 2026, 19:51 UTC

Arvinas Inc is rising amid a broader market rally, with no specific company news driving the move. The stock remains above its 20-day moving average.

6 ago 2026, 19:46 UTC

News

Arvinas Inc reported earnings per share of $2.58, exceeding estimates. Revenue reached $249.7 million, driving shares higher in Thursday's session.

5 ago 2026, 20:03 UTC

News

Arvinas shares are lower following Wells Fargo's downgrade to Equal-Weight and a price target cut to $11, despite Wedbush raising its target to $12.

4 ago 2026, 20:02 UTC

Social Media
News

Arvinas Inc shares rose following strong Q2 results, with EPS of $2.58 and revenue of $249.7 million, surpassing analyst expectations. BTIG reiterated its Buy rating.

3 ago 2026, 19:46 UTC

News

Arvinas Inc. shares are lower today, continuing a downward trend since Friday. Barclays raised its price target from $18.00 to $20.00 while maintaining an "overweight" rating.

31 jul 2026, 20:06 UTC

Arvinas Inc shares are declining amid broader market trends and rising Treasury yields. The stock remains below its 20-day moving average.

29 jul 2026, 16:36 UTC

Arvinas shares are lower today, trading near the lower end of their one-month range amid rising oil prices and inflation concerns.

28 jul 2026, 20:06 UTC

Arvinas Inc's shares are lower today, reflecting broader market trends amid a significant decline in Asian indices, particularly the Nikkei 225.

24 jul 2026, 19:26 UTC

Arvinas Inc. shares are lower amid a broader market decline influenced by falling crude oil prices, now near the lower end of their one-month range.

22 jul 2026, 20:06 UTC

Arvinas Inc. shares are near unchanged amid routine trading and cautious market sentiment ahead of the Federal Reserve meeting.

21 jul 2026, 20:06 UTC

Arvinas Inc shares are higher during Tuesday's session, tracking gains in the Nasdaq 100 Index amid strong technology sector performance. No specific news was identified.

Comparación entre iguales

Cambio de precio

Arvinas Inc previsión

Precio Objetivo

By TipRanks

80.51% repunte

Estimación a 12 Meses

Media 14.964 USD  80.51%

Máximo 21 USD

Mínimo 8.68 USD

De acuerdo con 11 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Arvinas Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

11 ratings

5

Comprar

6

Mantener

0

Vender

Sentimiento

By Acuity

115 / 339 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Arvinas Inc

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.